Blend Therapeutics Receives $21,000,000 New Financing Round

  • Feed Type
  • Date
  • Company Name
    Blend Therapeutics
  • Mailing Address
    134 Coolidge Avenue Watertown, MA 02472 USA
  • Company Description
    Blend is pioneering controlled combination medicines that overcome the limitations of conventional combination therapy through their unprecedented ability to hit distinct disease pathways with multiple drugs in concert—at the desired sites, at the most effective concentrations.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    The proceeds of the financing will enable Blend to fully exploit its proprietary Pentarin™ platform, unveiled today, which creates novel, miniaturized biologic drug conjugates encapsulated in nanoparticles, representing a new class of cancer therapeutics. Including the $21 million announced today, Blend has obtained a total of $39.8 million in funding to date.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy